Mohannad Mohammad S Alamri
Overview
Explore the profile of Mohannad Mohammad S Alamri including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
63
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Saber S, Alamri M, Alfaifi J, Saleh L, Abdel-Ghany S, Aboregela A, et al.
Pharmaceuticals (Basel)
. 2025 Jan;
18(1.
PMID: 39861197
[...].
2.
Fikry H, Saleh L, Mohammed O, Doghish A, Elsakka E, Hashish A, et al.
Life Sci
. 2024 Nov;
359:123220.
PMID: 39505296
Diabetic patients commonly experience hyposalivation, which can cause challenges with eating, swallowing, dry mouth, and speaking. It also raises the likelihood of developing periodontal disease. This study aimed to evaluate...
3.
Mohammed O, Youssef M, Hamad R, Abdel-Reheim M, Saleh L, Alamri M, et al.
PLoS One
. 2024 Oct;
19(10):e0312572.
PMID: 39480853
The development of new drugs for the inhibition of hepatocellular carcinoma (HCC) development and progression is a critical and urgent need. The median survival rate for HCC patients remains disappointingly...
4.
Mohammed O, Alghamdi M, Bahashwan E, AlQahtani A, Alfaifi A, Hassan R, et al.
Naunyn Schmiedebergs Arch Pharmacol
. 2024 Oct;
PMID: 39466441
Psoriasis is a sustainable skin disease characterized by inflammation resulting from the interaction between immune cells and keratinocytes. Significant advancements have been achieved in studying the molecular process behind noncoding...
5.
Alharthi M, Miskeen E, Alotaibi E, Ibrahim I, Alamri M, Alshahrani M, et al.
Healthcare (Basel)
. 2024 Aug;
12(16).
PMID: 39201233
Background: Hypertension imposes a significant public health burden. An increased awareness of hypertension complications within a population can positively impact patient care and prevent complications. This study seeks to assess...
6.
Hasan A, Cavalu S, Saber S, Doghish A, Hamad R, Abdel-Reheim M, et al.
Life Sci
. 2024 Jun;
351:122791.
PMID: 38848936
Sorafenib is a multikinase inhibitor employed for managing hepatocellular carcinoma (HCC). The emergence of sorafenib resistance presents an obstacle to its therapeutic efficacy. One notable approach to overcoming sorafenib resistance...
7.
Mohammed O, Youssef M, Doghish A, Hamad R, Abdel-Reheim M, Alghamdi M, et al.
Eur J Pharm Sci
. 2024 May;
198:106792.
PMID: 38714237
Non-alcoholic steatohepatitis (NASH) is characterized by liver inflammation, fat accumulation, and collagen deposition. Due to the limited availability of effective treatments, there is a pressing need to develop innovative strategies....
8.
Mohammed O, Alghamdi M, Adam M, BinAfif W, Alfaifi J, Alamri M, et al.
Int J Biol Macromol
. 2024 Apr;
268(Pt 2):131814.
PMID: 38677679
Epigenetic processes, including non-coding RNA, histone modifications, and DNA methylation, play a vital role in connecting the environment to the development of a disorder, especially when there is a favorable...
9.
Mohammed O, Saber S, Abdel-Reheim M, Alamri M, Alfaifi J, Adam M, et al.
Toxicol Appl Pharmacol
. 2024 Apr;
486:116943.
PMID: 38677600
Ulcerative colitis (UC) is an inflammatory condition that affects the colon's lining and increases the risk of colon cancer. Despite ongoing research, there is no identified cure for UC. The...
10.
Abdelhady R, Saber S, Abdel-Reheim M, Alamri M, Alfaifi J, Adam M, et al.
Front Pharmacol
. 2024 Mar;
15:1382529.
PMID: 38545556
[This corrects the article DOI: 10.3389/fphar.2023.1239025.].